Log In
BCIQ
Print this Print this
 

Subcutaneous Benlysta, belimumab

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionSubcutaneous formulation of a human mAb against BLyS (BAFF)
Molecular Target BLyS (BAFF)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationLupus
Indication DetailsTreat active, autoantibody-positive systemic lupus erythematosus (SLE); Treat active, autoantibody-positive systemic lupus erythematosus (SLE) in adults who have an inadequate response to standard therapy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today